517
Participants
Start Date
December 31, 2009
Primary Completion Date
July 31, 2012
Study Completion Date
June 30, 2013
tivozanib (AV-951)
Tivozanib: 1.5 mg orally once daily. Subjects will receive 1.5 mg tivozanib once daily beginning on Day 1 for 3 weeks followed by 1 week off treatment. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks.
Sorafenib
Sorafenib: 400 mg orally twice daily. Subjects will receive 400 mg (2 x 200 mg tablets) sorafenib twice daily continuously, beginning on Day 1. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks.
Site 404, Sofia
Site 400, Sofia
Site 102, Sante Fe
Site 403, Plovdiv
Site 402, Veliko Tarnovo
Site 401, Varna
Site 186, New York
Site 480, Belgrade
Site 481, Belgrade
Site 482, Belgrade
Site 130, Marseille
Site 491, Chernihiv
Site 483, Niš
Site 484, Kamenitz
Site 161, Pavia
Site 180, Gainesville
Site 184, Orlando
Site 133, Saint-Herblain
Site 498, Dnipropetrovsk
Site 492, Dniproperovsk
Site 160, Arezzo
Site 182, Minneapolis
Site 494, Kharkiv
Site 495, Zaporizhia
Site 187, Dallas
Site 490, Ivano-Frankivsk
Site 493, Donetsk
Site 496, Donetsk
Site 497, Uzhhorod
Site 185, Los Angeles
Site 454, Moscow
Site 154, Delhi
Site 453, Moscow
Site 458, Moscow
Site 460, Moscow
Site 461, Moscow
Site 462, Moscow
Site 464, Yaroslavi
Site 466, Saint Petersburg
Site 465, Saint Petersburg
Site 158, Lucknow
Site 456, Obninsk
Site 442, Timișoara
Site 191, Jaipur
Site 155, Jaipur
Site 457, Rostov-on-Don
Site 463, Pyatigorsk
Site 156, Ahmedabad
Site 153, Pune
Site 159, Pune
Site 452, Kazan'
Site 151, Nashik
Site 468, Yoshkar-Ola
Site 459, Ufa
Site 451, Chelyabinsk
Site 157, Hyderabad
Site 444, Brasov
Site 450, Nizhny Novgorod
Site 455, Yekaterinburg
Site 152, Vellore
Site 467, Omsk
Site 150, Kolkata
Site 190, Patna
Site 123, Temuco
Site 121, La Reina
Site 122, Santiago
Site 110, Montreal
Site 411, Prague
Site 423, Budapest
Site 421, Kaposvár
Site 422, Pécs
Site 424, Szombathely
Site 162, Roma
Site 432, Bialystok
Site 434, Bydgoszcz
Site 431, Gdansk
Site 435, Olsztyn
Site 433, Poznan
Site 430, Warsaw
Site 436, Warsaw
Site 441, Bucharest
Site 440, Bucharest
Site 443, Bucharest
Site 170, Cambridge
Site 173, Ipswich
Site 172, Leicester
Lead Sponsor
AVEO Pharmaceuticals, Inc.
INDUSTRY